ArticlebioRxiv : the preprint server for biology2025

Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma.

Ant Murphy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.